Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the popular weight-loss drug, Wegovy.
The Danish pharmaceutical giant and Hims & Hers had initially partnered in April, with plans for the telehealth company to offer Wegovy as part of a bundled package on its platform.
Despite the halt, Hims & Hers stated earlier this month that it intends to continue selling "personalised" doses of Wegovy, priced from approximately $165 a month. This approach, according to Hims, is permissible under clinical guidelines, citing reasons such as reduced side effects.
Hims also provides liraglutide, a generic version of an older Novo Nordisk diabetes medication known for its weight-loss effects, alongside branded Wegovy and Eli Lilly's competing drug, Zepbound.
Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it.
Hims & Hers was not immediately available for a comment outside of the company's regular work hours.
A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list.
"Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said.
Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims and Hers fell 22% to $50.02 in U.S. premarket hours.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
13 minutes ago
- New York Post
Toxic ‘muscle mommy' versus ‘Pilates princess' trend can have lasting negative effects, experts say
'Thin is in' — again — and social media is to blame, critics say. The rise of trendy weight-loss drugs like Ozempic has turbocharged a new wave of toxic body standards. But it's not just the shots fueling the shift. In digital wellness circles, a not-so-subtle transformation is playing out. People are ditching the 'muscle mommy' aesthetic and opting for the pilates look instead. Kalim – Once celebrated for strength and powerlifting prowess, the 'muscle mommy' movement — a term used to describe strong, muscular women who strength train — is being replaced by a wave of Pilates-obsessed influencers pushing a leaner, daintier aesthetic, which was originally reported on by PureWow. After years of hyping up CrossFit and lifting heavy in the name of being 'strong, not skinny,' gym-goers on TikTok and Instagram are now sharing why they've ditched heavy deadlifts for leg circles, blaming weights for making them look too beefy. And sadly, these people pushing their pilates obsession are creating a bigger problem. Pilates-obsessed people are creating a bigger problem without even realizing it. Vasyl – Body types shouldn't be a trend, critics argue, warning that this narrow image of what a 'fit' body should look like may actually discourage people from working out altogether — or worse, spiral them into obsessive, unhealthy routines. Case in point: TikTok is filled with videos of women analyzing their bodies, torn between the 'muscle mommy' look or the 'Pilates princess' aesthetic. Social media videos captioned 'Pilates hourglass' and 'pilates body > gym body' are just adding to a body insecurity epidemic among women. 'It's important to remember that exercise is about feeling strong and healthy, not fitting a certain look. Enjoying Pilates or any workout doesn't mean you have to look like the people you see online,' Dr. Sanam Hafeez, a neuropsychologist based in New York City, told PureWow. 'Seeing the same body type repeatedly on social media can make people feel like they have to look that way to be accepted,' she told the outlet. Hafeez said that comparing your body to others online leads to low self-esteem. 'It can also make people feel like their worth depends on how they look, instead of who they are. This pressure can lead to harmful habits.' The 'muscle mommy' versus 'Pilates princess' debate even made its way to Reddit, where an entire thread exists of women sharing their thoughts about the toxicity of all of it. 'Yes! Do both, do it ALL. I lift heavy, do yoga and pilates, work on Hiit and cardio, dance my heart out. Life is meant for movement, and different ways of moving bring different joys,' shared on user. ''Muscle Mommy' always has and forever will make me want to f—ing vomit. I hate it so much,' quipped someone else. 'It's such a dumb thing to pit pilates and lifting against each other, as they both support and enhance one another. Pilates alone is great, as is lifting, but I've found pilates and yoga have both supported my range of motion, breathing, flexibility, and endurance to assist in progressing with lifting, esp after lengthy breaks…' a logical person pointed out. At the end of the day, people should move their bodies whichever way they want to — not how social media is telling them to.
Yahoo
an hour ago
- Yahoo
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it. When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk's NovoCare Pharmacy for a discounted price of $499 per month, in addition to Hims' monthly subscription fee. Hims has also continued to sell "personalized" doses of compounded semaglutide -- the main active ingredient in Wegovy -- for $165 per month, according to its website. Wegovy is approved by the U.S. Food and Drug Administration for weight loss in people with obesity or who are overweight with additional risks for cardiovascular disease. In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'" "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Operations, said in a news release Monday. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety -- and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Wegovy to be sold on Hims, Ro and LifeMD for reduced price Hims & Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients. "We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice," Dudum said. "We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. He continued, "We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients." Hims & Hers did not immediately reply to ABC News' request for further clarification about Wegovy remaining available on the platform. A spokesperson for Novo Nordisk told ABC News they have no additional comment. Compound drugs are copies of FDA-approved medications. They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take a version of a drug made by a pharmaceutical company and they need an alternative. In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity. The FDA has declared the shortages as "resolved," removing the drugs from its shortage list. Super Bowl ad for Hims & Hers' weight loss drug sparks backlash Last week, a federal judge in Texas upheld the FDA's decision to remove semaglutide from the shortage list, blocking compounding pharmacies from making copies of Wegovy and Ozempic, according to court documents.
Yahoo
an hour ago
- Yahoo
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it. When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk's NovoCare Pharmacy for a discounted price of $499 per month, in addition to Hims' monthly subscription fee. Hims has also continued to sell "personalized" doses of compounded semaglutide -- the main active ingredient in Wegovy -- for $165 per month, according to its website. Wegovy is approved by the U.S. Food and Drug Administration for weight loss in people with obesity or who are overweight with additional risks for cardiovascular disease. In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'" "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Operations, said in a news release Monday. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety -- and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Wegovy to be sold on Hims, Ro and LifeMD for reduced price Hims & Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients. "We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice," Dudum said. "We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. He continued, "We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients." Hims & Hers did not immediately reply to ABC News' request for further clarification about Wegovy remaining available on the platform. A spokesperson for Novo Nordisk told ABC News they have no additional comment. Compound drugs are copies of FDA-approved medications. They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take a version of a drug made by a pharmaceutical company and they need an alternative. In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity. The FDA has declared the shortages as "resolved," removing the drugs from its shortage list. Super Bowl ad for Hims & Hers' weight loss drug sparks backlash Last week, a federal judge in Texas upheld the FDA's decision to remove semaglutide from the shortage list, blocking compounding pharmacies from making copies of Wegovy and Ozempic, according to court documents.
